Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
14.22
+0.07 (0.49%)
Jun 18, 2026, 4:00 PM EDT - Market closed

Janux Therapeutics Stock Forecast

Stock Price Forecast

According to 18 analysts polled by S&P Global, Janux Therapeutics stock has a consensus rating of "Buy" and an average price target of $40.56. The average 1-year stock price forecast is 185.23% higher than the current stock price, while the lowest is $14 (-1.55%) and the highest is $80 (+462.59%).

Price Target: $40.56 (+185.23%)
Analyst Consensus: Buy
TargetLowAverageMedianHigh
Price$14$40.56$37$80
Change-1.55%+185.23%+160.20%+462.59%
* Price targets were last updated on May 11, 2026.

Analyst Ratings

The average analyst rating for Janux Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

RatingDec '25Jan '26Feb '26Mar '26Apr '26May '26
Strong Buy151514141313
Buy333322
Hold111122
Sell000011
Strong Sell000000
Total191918181818

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Evercore ISI
Evercore ISI
Buy
Maintains
$23$22
BuyMaintains$23$22+54.71%May 11, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$45
BuyReiterates$45+216.46%May 11, 2026
LifeSci Capital
LifeSci Capital
Buy
Reiterates
$60
BuyReiterates$60+321.94%May 8, 2026
Wedbush
Wedbush
Buy
Reiterates
$45$36
BuyReiterates$45$36+153.16%May 8, 2026
Guggenheim
Guggenheim
Buy
Reiterates
$68$58
BuyReiterates$68$58+307.88%May 8, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
31.04M
from 10.00M
Increased by 210.44%
Revenue Next Year
6.95M
from 31.04M
Decreased by -77.61%
EPS This Year
-1.79
from -1.83
EPS Next Year
-2.77
from -1.79
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
3.64M8.61M8.08M10.59M10.00M31.04M
Revenue Growth
-136.79%-6.14%30.99%-5.55%210.44%
Gross Profit
-22.60M-44.83M-46.84M-57.80M-115.90M31.04M
Gross Margin
-621.39%-520.54%-579.48%-545.90%-1,158.96%100.00%
Operating Income
-32.93M-67.09M-72.98M-98.85M-157.67M-141.56M
Net Income
-32.67M-63.06M-58.29M-68.99M-113.63M-108.82M
EPS
-----1.83-1.79
Free Cash Flow
577.38K-30.56M-29.52M-26.14M-51.27M-143.90M
No. Analysts
-----13
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High68.2M
Avg31.0M
Low3.7M

Revenue Growth

Revenue Growth202620272028
High
581.6%
Avg
210.4%
Low
-63.0%

EPS Forecast

EPS202620272028
High-0.81
Avg-1.79
Low-2.54

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-